Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

Similar articles for PubMed (Select 10812040)

1.

A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling.

Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C.

Biol Psychiatry. 2000 May 1;47(9):813-7.

PMID:
10812040
2.

A single-blind study of 'as-needed' ecopipam for gambling disorder.

Grant JE, Odlaug BL, Black DW, Fong T, Davtian M, Chipkin R, Kim SW.

Ann Clin Psychiatry. 2014 Aug;26(3):179-86.

PMID:
25166480
3.

A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers.

Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LR, Donahue CB, Kim SW.

J Clin Psychiatry. 2014 Jan;75(1):39-45. doi: 10.4088/JCP.13m08411.

PMID:
24345329
4.

Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder.

Tikka SK, Garg S, Das B.

Indian J Pharmacol. 2013 Sep-Oct;45(5):532-3. doi: 10.4103/0253-7613.117760.

5.

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.

Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ.

J Dev Behav Pediatr. 2013 Apr;34(3):147-55. doi: 10.1097/DBP.0b013e318287cd17.

6.

Amantadine in the treatment of pathological gambling: a case report.

Pettorruso M, Martinotti G, Di Nicola M, Onofrj M, Di Giannantonio M, Conte G, Janiri L.

Front Psychiatry. 2012 Nov 27;3:102. doi: 10.3389/fpsyt.2012.00102. eCollection 2012.

7.

Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S.

J Psychiatr Res. 2013 Feb;47(2):175-80. doi: 10.1016/j.jpsychires.2012.09.015. Epub 2012 Oct 9.

PMID:
23063327
8.

A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.

Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M.

J Clin Psychopharmacol. 2012 Oct;32(5):593-601. doi: 10.1097/JCP.0b013e3182664cfc.

PMID:
22926591
9.

An open-label trial of acamprosate in the treatment of pathological gambling.

Black DW, McNeilly DP, Burke WJ, Shaw MC, Allen J.

Ann Clin Psychiatry. 2011 Nov;23(4):250-6.

PMID:
22073381
10.

A double-blind, placebo-controlled trial of topiramate for pathological gambling.

Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E.

World J Biol Psychiatry. 2013 Mar;14(2):121-8. doi: 10.3109/15622975.2011.560964. Epub 2011 Apr 12.

PMID:
21486110
11.

Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study.

Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW.

Psychopharmacology (Berl). 2010 Dec;212(4):603-12. doi: 10.1007/s00213-010-1994-5. Epub 2010 Aug 19.

12.

Pathological gambling in Parkinson disease is reduced by amantadine.

Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M.

Ann Neurol. 2010 Sep;68(3):400-4. doi: 10.1002/ana.22029.

PMID:
20687121
13.

Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.

Koran LM, Bromberg D, Hornfeldt CS, Shepski JC, Wang S, Hollander E.

Compr Psychiatry. 2010 Jul-Aug;51(4):373-9. doi: 10.1016/j.comppsych.2009.10.001. Epub 2009 Dec 21.

PMID:
20579510
14.

[Customized pharmacotherapies in schizophrenia].

Suzuki Y, Fukui N, Watanabe J, Ono S, Sugai T, Tsuneyama N, Someya T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Apr;30(2):77-81. Review. Japanese.

PMID:
20491281
16.

Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine.

Chung SK, You IH, Cho GH, Chung GH, Shin YC, Kim DJ, Choi SW.

Yonsei Med J. 2009 Jun 30;50(3):441-4. doi: 10.3349/ymj.2009.50.3.441. Epub 2009 Jun 24.

17.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
18.

Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.

Vezmar S, Miljkovic B, Vucicevic K, Timotijevic I, Prostran M, Todorovic Z, Pokrajac M.

J Pharmacol Sci. 2009 May;110(1):98-104.

19.

Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.

Reinblatt SP, DosReis S, Walkup JT, Riddle MA.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):119-26. doi: 10.1089/cap.2008.040.

20.

A pilot study of impulsivity and compulsivity in pathological gambling.

Blanco C, Potenza MN, Kim SW, Ibáñez A, Zaninelli R, Saiz-Ruiz J, Grant JE.

Psychiatry Res. 2009 May 15;167(1-2):161-8. doi: 10.1016/j.psychres.2008.04.023. Epub 2009 Apr 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk